Samet Yildirim is the co-founder and chief operating officer at Orbillion Bio. His group is responsible for product development, manufacturing, and regulatory, as well as the business functions for strategy, marketing, and finance. Prior to Orbillion Bio, Samet was the head of Global Technology & Innovation Management at Boehringer Ingelheim Biopharma Business Unit. In this role, he was co-leading the innovation strategy and over 100 projects in the global portfolio. Yildirim joined Boehringer Ingelheim in Fremont, CA, in 2013 and was involved in the development of the iSKID™ continuous processing system. In 2015, he became a technology manager and developed a global innovation portfolio for the company’s Next Generation Manufacturing and Digitalization programs. Prior to Boehringer Ingelheim, Yildirim held various positions with responsibilities for research, product innovation, and business development in life science companies. He received a BSc in Biology, an MSc in Biophysics from Ankara University, and a Master of Business and Science (MBS) degree in bioprocessing from KGI.